Boehringer offers unbranded biosimilar at 81% discount to AbbVie’s Humira Business, Therapeutics Boehringer Ingelheim on Monday unveiled lower wholesale pricing for its adalimumab-adbm injection, the company’s interchangeable biosimilar to AbbVie’s blockbuster chronic inflammatory therapy Humira (adalimumab). Read more October 3, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/10/BioSpaceBI10-3-2023.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-10-03 10:21:492023-10-04 10:42:36Boehringer offers unbranded biosimilar at 81% discount to AbbVie’s Humira
